Compounds > arsenic trioxide
Page last updated: 2024-08-21

arsenic trioxide and Angiogenesis, Pathologic

arsenic trioxide has been researched along with Angiogenesis, Pathologic in 32 studies

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's14 (43.75)29.6817
2010's14 (43.75)24.3611
2020's4 (12.50)2.80

Authors

AuthorsStudies
Dong, S; Gao, J; Kong, J; Li, Z; Sun, W; Wu, S1
Bo, P; Fu, X; Guo, S; Kuang, T; Li, L; Liu, S; Xiang, X; Xie, X; Zhang, Y1
Bai, L; Cao, Y; Huang, Q; Shao, X; Sun, Z; Wang, L; Wu, M; Wu, Y; Xing, Y; Zhao, Y1
Chen, D; Chen, Y; Jiang, X; Li, D; Li, H; Shan, H; Wang, W1
Fu, Y; Guo, BB; Jiang, HY; Li, S; Liu, LY; Wang, KK; Wu, CJ; Zhang, CM; Zhang, F; Zhang, Y1
Chahardouli, B; Ghavamzadeh, A; Mohammadi Kian, M; Mohammadi, S; Nikbakht, M; Rostami, S; Tavallaei, M; Zahedpanah, M1
Chen, L; Du, J; Gu, L; Liu, L; Wang, Y; Wu, Y; Zhan, S; Zhang, L; Zhang, Y1
Jiang, F; Li, Y; Li, Z; Si, L; Zhang, Z1
Chang, KJ; Jin, YX; Li, B; Yang, MH; Zhao, XW; Zheng, JC1
Chen, YR; Dou, MM; Li, PC; Yang, S; Zhang, J; Zhao, XY1
Fu, HQ; Huang, MW; Wang, K; Wang, KY; Wu, LQ; Yin, XB; Yu, X; Zhou, F1
Chen, K; Huang, H; Li, B; Sun, GY; Yang, MH; Zang, YS; Zhao, XW1
Jiang, F; Li, Y; Li, Z; Liu, Q; Shen, J; Wang, X; Zhang, J1
Cao, Z; Chen, X; Cui, L; Gao, B; Zhang, S; Zhang, W1
Gao, Q; Krebsbach, PH; Kumar, P; Ning, Y; Polverini, PJ; Wang, Z1
Gotlib, J; Oh, ST1
Chen, BA; Liu, L; Qin, SK1
Chen, YJ; Li, HM; Li, XJ; Li, ZH; Liang, Y; Long, Y; Qing, C; Yu, M; Zhang, XM; Zhang, YL1
Abboud, CN; Cashen, AF; DiPersio, JF; Gao, F; Hassan, A; Klco, JM; Procknow, E; Stockerl-Goldstein, KE; Uy, GL; Vij, R; Welch, JS; Westervelt, P1
Aguayo, A; Armillas-Canseco, FM; Martínez-Baños, D1
Bertola, A; Boccadoro, M; Bruno, B; Giaccone, L; Massaia, M; Palumbo, A; Rotta, M1
Sekeres, MA1
Cardinale, G; Gervasi, F; Pagnucco, G1
Alimoghaddam, K; Ghavamzadeh, A; Jahani, M; Rostami, S; Sanaat, Z; Shariftabrizi, A; Tavangar, M; Tavangar, SM1
He, W; Hu, Y; Sun, C; Wang, Y; Zhang, X1
Dong, X; Jiang, H; Krissansen, GW; Liu, B; Pan, S; Qiao, H; Sun, X1
Chen, X; Liu, SX; Ren, LF; Wu, DD; Xiao, YF1
Dong, X; Liu, Y; Sun, X; Zhang, J; Zhang, X; Zhao, S; Zou, H1
Dias, S; Lam, G; Lane, WJ; Rafii, S; Roboz, GJ; Soignet, SL; Warrell, RP1
Hussein, MA1
List, AF1
Davison, K; Mann, KK; Miller, WH1

Reviews

7 review(s) available for arsenic trioxide and Angiogenesis, Pathologic

ArticleYear
Antiangiogenesis in myelodysplastic syndrome.
    Current cancer drug targets, 2011, Volume: 11, Issue:9

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Thalidomide

2011
New drugs for treatment of multiple myeloma.
    The Lancet. Oncology, 2004, Volume: 5, Issue:7

    Topics: 2-Methoxyestradiol; Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Diphosphonates; Enzyme Inhibitors; Estradiol; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Thalidomide

2004
Arsenic trioxide as a treatment for myelodysplastic syndrome.
    Current hematology reports, 2005, Volume: 4, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Cell Division; Clinical Trials as Topic; Dexamethasone; DNA-Binding Proteins; Drug Therapy, Combination; Glutathione; Hematologic Neoplasms; Humans; Leukemia, Promyelocytic, Acute; MDS1 and EVI1 Complex Locus Protein; Multicenter Studies as Topic; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Proto-Oncogenes; Transcription Factors

2005
Targeting multiple myeloma cells and their bone marrow microenvironment.
    Annals of the New York Academy of Sciences, 2004, Volume: 1028

    Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow Cells; Boronic Acids; Bortezomib; Cell Adhesion; Cytokines; Disease Progression; Disease-Free Survival; Humans; Ligands; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Protease Inhibitors; Pyrazines; Signal Transduction; Thalidomide

2004
Nontraditional cytotoxic therapies for relapsed/refractory multiple myeloma.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Cell Adhesion Molecules; Cytokines; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Pyrazines; Thalidomide; Treatment Outcome

2002
New approaches to the treatment of myelodysplasia.
    The oncologist, 2002, Volume: 7 Suppl 1

    Topics: Amifostine; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Enzyme Inhibitors; Humans; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Prognosis; Proto-Oncogene Mas; Risk Factors; Severity of Illness Index; Thalidomide; Topotecan; Treatment Outcome

2002
Arsenic trioxide: mechanisms of action.
    Seminars in hematology, 2002, Volume: 39, Issue:2 Suppl 1

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Division; Glutathione; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neovascularization, Pathologic; Oncogene Proteins, Fusion; Oxides; Recurrence

2002

Trials

2 trial(s) available for arsenic trioxide and Angiogenesis, Pathologic

ArticleYear
Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.
    American journal of hematology, 2011, Volume: 86, Issue:9

    Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Azacitidine; Bone Marrow; Bone Marrow Cells; Cohort Studies; Decitabine; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Young Adult

2011
Anti-leukemic and anti-angiogenesis efficacy of arsenic trioxide in new cases of acute promyelocytic leukemia.
    Leukemia & lymphoma, 2006, Volume: 47, Issue:1

    Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Bone Marrow; Disease Progression; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Promyelocytic, Acute; Leukocytosis; Male; Middle Aged; Neovascularization, Pathologic; Oxides; Recurrence; Remission Induction; Survival Rate; Time Factors; Treatment Outcome

2006

Other Studies

23 other study(ies) available for arsenic trioxide and Angiogenesis, Pathologic

ArticleYear
Arsenic trioxide inhibits angiogenesis of hepatocellular carcinoma after insufficient radiofrequency ablation via blocking paracrine angiopoietin-1 and angiopoietin-2.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2022, Volume: 39, Issue:1

    Topics: Angiopoietin-1; Angiopoietin-2; Animals; Arsenic Trioxide; Carcinoma, Hepatocellular; Cell Line, Tumor; Endothelial Cells; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Radiofrequency Ablation

2022
7‑Difluoromethyl‑5,4'‑dimethoxygenistein exerts anti‑angiogenic effects on acute promyelocytic leukemia HL‑60 cells by inhibiting the TLR4/NF‑κB signaling pathway.
    Molecular medicine reports, 2020, Volume: 21, Issue:5

    Topics: Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Chick Embryo; Genistein; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neovascularization, Pathologic; NF-kappa B; Signal Transduction; Toll-Like Receptor 4

2020
Antiangiogenic effect of arsenic trioxide in HUVECs by FoxO3a-regulated autophagy.
    Journal of biochemical and molecular toxicology, 2021, Volume: 35, Issue:5

    Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Autophagy; Forkhead Box Protein O3; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic

2021
Hypoxic Hepatocellular Carcinoma Cells Acquire Arsenic Trioxide Resistance by Upregulating HIF-1α Expression.
    Digestive diseases and sciences, 2022, Volume: 67, Issue:8

    Topics: Animals; Arsenic Trioxide; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A

2022
Low dosage of arsenic trioxide inhibits vasculogenic mimicry in hepatoblastoma without cell apoptosis.
    Molecular medicine reports, 2018, Volume: 17, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Male; Mice, Nude; Neovascularization, Pathologic; Oxides; Xenograft Model Antitumor Assays

2018
Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells
    Asian Pacific journal of cancer prevention : APJCP, 2018, Apr-27, Volume: 19, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Oxides; Thalidomide; U937 Cells; Vascular Endothelial Growth Factors

2018
Arsenic Trioxide Suppressed Migration and Angiogenesis by Targeting FOXO3a in Gastric Cancer Cells.
    International journal of molecular sciences, 2018, Nov-24, Volume: 19, Issue:12

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2018
Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
    Cell biology and toxicology, 2019, Volume: 35, Issue:4

    Topics: Arsenic Trioxide; Cell Line, Tumor; Enhancer of Zeste Homolog 2 Protein; Female; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; NF-kappa B; Oncogene Protein p65(gag-jun); Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms; Vascular Endothelial Growth Factor A

2019
Arsenic Trioxide Inhibits the Metastasis of Small Cell Lung Cancer by Blocking Calcineurin-Nuclear Factor of Activated T Cells (NFAT) Signaling.
    Medical science monitor : international medical journal of experimental and clinical research, 2019, Mar-26, Volume: 25

    Topics: Animals; Arsenic Trioxide; Calcineurin; Cell Movement; Cell Proliferation; China; DNA-Binding Proteins; Endothelium, Vascular; Human Umbilical Vein Endothelial Cells; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Nude; Muscle Proteins; Neoplasm Metastasis; Neovascularization, Pathologic; NFATC Transcription Factors; Receptors, CXCR; rho GTP-Binding Proteins; Signal Transduction; Small Cell Lung Carcinoma; Up-Regulation; Vascular Endothelial Growth Factor A

2019
Resveratrol and arsenic trioxide act synergistically to kill tumor cells in vitro and in vivo.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Necrosis; Neovascularization, Pathologic; Oxides; Reactive Oxygen Species; Resveratrol; Stilbenes; Tumor Burden; Xenograft Model Antitumor Assays

2014
Inhibitory effect of humanized anti-VEGFR-2 ScFv-As2O3-stealth nanoparticles conjugate on growth of human hepatocellular carcinoma: in vitro and in vivo studies.
    Asian Pacific journal of tropical medicine, 2014, Volume: 7, Issue:5

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Delivery Systems; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Microvessels; Nanoparticles; Neovascularization, Pathologic; Oxides; Single-Chain Antibodies; Vascular Endothelial Growth Factor Receptor-2

2014
Arsenic trioxide exerts anti-lung cancer activity by inhibiting angiogenesis.
    Current cancer drug targets, 2014, Volume: 14, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Angiogenesis Inhibitors; Animals; Arsenic Trioxide; Arsenicals; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; Receptor, Notch1; Signal Transduction; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2014
Inhibition of TGF-β/SMAD3/NF-κB signaling by microRNA-491 is involved in arsenic trioxide-induced anti-angiogenesis in hepatocellular carcinoma cells.
    Toxicology letters, 2014, Nov-18, Volume: 231, Issue:1

    Topics: 3' Untranslated Regions; Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Methylation; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; MicroRNAs; Neovascularization, Pathologic; Neovascularization, Physiologic; NF-kappa B; Oxides; RNA Interference; Signal Transduction; Smad3 Protein; Time Factors; Transfection; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A

2014
Downregulation of B7-H4 in the MHCC97-H hepatocellular carcinoma cell line by arsenic trioxide.
    Molecular medicine reports, 2016, Volume: 13, Issue:3

    Topics: Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Liver Neoplasms; Matrix Metalloproteinase 2; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Oxides; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; V-Set Domain-Containing T-Cell Activation Inhibitor 1; Vascular Endothelial Growth Factor A

2016
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:7

    Topics: Animals; Arsenic Trioxide; Arsenicals; Bone and Bones; Bone Resorption; Carcinoma, Squamous Cell; Cell Death; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Mouth Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Osteoblasts; Oxides; Radiation, Ionizing; Treatment Outcome; Tumor Stem Cell Assay; Vascular Endothelial Growth Factor A

2008
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?
    Current hematologic malignancy reports, 2008, Volume: 3, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arsenic Trioxide; Arsenicals; Bevacizumab; Clinical Trials as Topic; Drug Approval; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Lenalidomide; Myelodysplastic Syndromes; Neovascularization, Pathologic; Oxides; Protein-Tyrosine Kinases; Thalidomide

2008
[Anti-angiogenesis effect of arsenic trioxide plus cinobufacin on human hepatocarcinoma transplantation model nude mice].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2011, Volume: 31, Issue:1

    Topics: Amphibian Venoms; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; Phytotherapy; Xenograft Model Antitumor Assays

2011
Arsenic trioxide induces apoptosis of Burkitt lymphoma cell lines through multiple apoptotic pathways and triggers antiangiogenesis.
    Oncology research, 2011, Volume: 19, Issue:3-4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Burkitt Lymphoma; Cell Proliferation; Flow Cytometry; Humans; Inhibitor of Apoptosis Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Oxides; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survivin; Vascular Endothelial Growth Factor A

2011
Mechanism of arsenic trioxide inhibiting angiogenesis in multiple myeloma.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:1

    Topics: Angiogenesis Inhibitors; Arsenic Trioxide; Arsenicals; Brain-Derived Neurotrophic Factor; Cell Line, Tumor; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Multiple Myeloma; Neovascularization, Pathologic; Oxides; Receptor, trkB

2006
Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
    Cancer science, 2006, Volume: 97, Issue:7

    Topics: Animals; Antineoplastic Agents; Aorta; Apoptosis; Arsenic Trioxide; Arsenicals; Cattle; Cell Proliferation; Endothelial Cells; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Oxides; Vascular Endothelial Growth Factor A

2006
Inhibitory effect of arsenic trioxide on angiogenesis and expression of vascular endothelial growth factor in gastric cancer.
    World journal of gastroenterology, 2006, Sep-28, Volume: 12, Issue:36

    Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Oxides; RNA, Messenger; Stomach Neoplasms; Time Factors; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays

2006
Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Drug Stability; Glioma; Injections, Intravenous; Liposomes; Male; Microscopy, Electron; Neovascularization, Pathologic; Oxides; Rats; Rats, Wistar; Tissue Distribution

2008
Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis.
    Blood, 2000, Aug-15, Volume: 96, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cells, Cultured; Dose-Response Relationship, Drug; Endothelium, Vascular; Humans; Leukemia; Neovascularization, Pathologic; Oxides; Time Factors

2000